Appetite is influenced by a complex network of hormones, nerves, the digestive system and the brain. Among the hormones involved is glucagon-like peptide-1 (GLP-1), a naturally occurring hormone that helps regulate appetite, feelings of fullness and blood glucose.
Prescription GLP-1 receptor agonists interact with this biological pathway and are prescribed for specific medical conditions when a licensed healthcare provider determines they are appropriate. Researchers continue to study how GLP-1 receptor activity influences appetite regulation and eating behaviors. However, many questions remain, particularly regarding food cravings and reward-related behaviors.
Understanding the difference between hunger, appetite and cravings can help patients develop realistic expectations and support long-term lifestyle changes.
GLP-1 is released naturally after eating and helps coordinate communication between the digestive tract, pancreas and brain.
Research suggests this signaling contributes to:
GLP-1 receptor agonists are designed to interact with this pathway. Treatment decisions should always be individualized and based on a patient's medical history, health goals and evaluation by a licensed healthcare provider.
Although these terms are often used interchangeably, they describe different biological and behavioral experiences.
Hunger is the body's physiological need for nourishment. It develops as the body requires energy and nutrients.
Appetite is the desire to eat. It can be influenced by hunger, but it is also affected by routines, social situations, emotions, environmental cues and learned behaviors.
Food cravings involve a strong desire for a particular food or drink. Cravings may occur with or without physical hunger and often reflect a combination of biological, psychological and environmental influences.
Because these experiences are different, addressing appetite alone may not resolve every reason a person wants to eat.
"Food noise" is an informal term that has become popular on social media and in patient communities. It generally refers to persistent thoughts about food, eating or the next meal.
People may describe food noise as:
Food noise is not a recognized medical diagnosis. Researchers continue to explore how appetite regulation and eating behaviors interact with cognitive and emotional processes, but no single medical definition currently exists.
Eating behaviors are influenced by much more than physical hunger.
Stress, boredom, anxiety, celebrations, social gatherings, habits and emotions can all affect when and why someone chooses to eat.
For individuals who struggle with emotional eating, healthcare providers may recommend a comprehensive approach that includes nutrition guidance, stress management strategies and behavioral health support when appropriate.
Binge-eating disorder is a recognized mental health condition characterized by recurrent episodes of consuming unusually large amounts of food while experiencing a loss of control.
Diagnosis and treatment require evaluation by qualified healthcare professionals. Treatment plans may include psychotherapy, nutrition counseling, medical care and other evidence-based interventions.
Individuals experiencing distress related to eating behaviors should seek professional evaluation rather than relying on information found online.
Researchers have identified GLP-1 receptors in several areas involved in appetite regulation and reward processing.
The brain's reward system is highly complex. It involves communication among multiple brain regions, hormones, neurotransmitters and learned behaviors that influence motivation and decision-making.
Because of this complexity, scientists continue to investigate how GLP-1 receptor activity may interact with reward pathways. Current research is ongoing, and additional independent human studies are needed before conclusions can be drawn about specific behaviors.
Researchers have also explored whether GLP-1 receptor activity may influence behaviors related to alcohol and other substances.
Although early research has generated interest, the available evidence remains limited and continues to evolve. GLP-1 medications are not established treatments for alcohol use disorder, nicotine dependence or other substance use disorders.
Anyone experiencing concerns related to alcohol or substance use should seek evaluation from an appropriately qualified healthcare professional.
Medication is only one component of a comprehensive health plan.
Healthcare providers often encourage patients to focus on:
Consuming nutrient-dense foods that support overall health while meeting individual nutritional needs.
Participating in regular movement appropriate for age, health status and personal abilities.
Maintaining adequate fluid intake throughout the day.
Developing consistent sleep habits that support metabolic health and overall well-being.
Regular communication with a healthcare provider allows treatment plans to be adjusted as health needs change.
A licensed healthcare provider may determine that a compounded medication is appropriate based on an individual's clinical needs and applicable compounding regulations.
Compounded medications may differ from FDA-approved drug products in formulation, inactive ingredients, manufacturing processes and regulatory review.
Compounded drugs are not FDA approved. This means that the FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
Compounded medications should not be described as generic, identical to or interchangeable with FDA-approved medications.
Before beginning treatment, consider asking:
GLP-1 receptor activity plays an important role in appetite regulation, and researchers continue to study how these biological pathways influence eating behaviors and reward processing.
While scientific interest in food cravings and reward-related behaviors continues to grow, many questions remain unanswered. These medications should not be presented as established treatments for eating disorders, alcohol use disorder or other substance use disorders.
Long-term health is best supported through individualized medical care, healthy lifestyle habits and ongoing communication with a licensed healthcare provider.
TeleWellnessMD® connects patients with licensed healthcare providers who can evaluate your medical history, discuss your health goals and determine whether treatment may be appropriate for your individual needs.
This content is for educational and informational purposes only and should not be interpreted as medical advice. TeleWellnessMD® is a technology platform that connects patients with licensed healthcare providers. TeleWellnessMD® does not practice medicine, provide medical advice, or dispense medications. All therapies require evaluation and approval by a licensed healthcare provider. Results may vary. Prescription required. Compounded drugs are not FDA approved. This means that the FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
Berthoud HR. The Neurobiology of Food Intake in an Obesogenic Environment. Proceedings of the Nutrition Society. 2012.
Berridge KC. From Prediction Error to Incentive Salience: Mesolimbic Computation of Reward Motivation. European Journal of Neuroscience. 2012.
Morton GJ, Meek TH, Schwartz MW. Neurobiology of Food Intake in Health and Disease. Nature Reviews Neuroscience. 2014.
Chomiuk T, Niezgoda N, Mamcarz A, Śliż D. Physical Activity in Metabolic Syndrome. Frontiers in Physiology. 2024.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Arlington, VA: American Psychiatric Association; 2022.